Researchers aimed to identify potential serum metabolite biomarkers for feline mammary carcinomas using liquid chromatography-mass spectrometry (LC-MS) and multiple reaction monitoring (MRM) techniques. The results of the study identified 12 metabolites that were significantly different in cats having mammary carcinoma, including lysophosphatidylcholines, sphingomyelins, and glycerophospholipids. The identified metabolites were involved in various metabolic pathways, including Glycerophospholipid metabolism, Sphingolipid metabolism, and Fatty acid metabolism. The study concluded that the identified metabolites could serve as potential serum biomarkers for feline mammary carcinomas. Gameiro and colleagues studied the molecular mechanisms of FMC development and utilized knowledge from human breast-cancer research to identify diagnostic and prognostic biomarkers. Their research offers insights into potential therapeutic options for specific subtypes of FMC, such as HER2positive and triple-negative FMC. This study highlights the importance of using cats as a cancer model to advance our understanding of FMC and develop effective treatments. The broad study of Wei and co-authors reveals that metabolites obtained using untargeted and targeted metabolomics allow to distinguish different stages of breast cancer in women. There were revealed 15 targeted metabolites with fold change 0.54-2.20 and p-value < 0.025 and 33 untargeted metabolites with fold change 0.46-2.24 and p-value < 0.049. Yu and colleagues identified canine mammary tumor-associated metabolites using untargeted metabolomics. The study revealed 536 differential metabolites that were analyzed with MetaboAnalyst 4.0 and showed most significant pathways: Purine metabolism, Alpha-linolenic acid metabolism, Vitamin B6 metabolism, and Fatty acid biosynthesis.